The Pharmaceutical Research Center (PRC) is responsible for the safe and ethical provision of investigational/study medications to research subjects enrolled in clinical drug trials within the University of Wisconsin Hospital and Clinics (UWHC) and the University of Wisconsin Carbone Cancer Center (UWCCC). The PRC service ensures that drug research protocols proceed optimally through UWHC's established medication use system and in accordance with all federal, state, institutional and sponsor regulations governing clinical research. While the PRC program supports all UW-Madison investigators conducting clinical drug research, its relationship with UWCCC is unique in its level of commitment, the breadth and depth of services provided and its expertise in handling biohazardous and gene therapy products. The PRC provides detailed protocol review and feasibility assessment within the confines of an academic medical center. It ensures full compliance with federal, state, sponsor and institutional requirements through activities such as;establishment of drug handling/distribution/preparation/destruction procedures;creation of investigational drug monographs for health care providers;education of healthcare staff regarding protocol procedures;creation of preprinted physician orders and prescriptions;drug inventory management and accountability;drug preparation and/or oversight;quality assurance audits;and protocol amendment management. It operates satellite pharmacy locations, optimizing ability to extend clinical research into the community. The services are continually refined and expanded to meet the evolving needs of UWCCC research faculty, research infrastructure and the research subject.
The Pharmaceutical Research Center is responsible for the safe and ethical provision of study medications to research subjects enrolled in clinical drug trials within the University of Wisconsin Hospital and Clinics and the University of Wisconsin Carbone Cancer Center.
|Ni, Dalong; Jiang, Dawei; Kutyreff, Christopher J et al. (2018) Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nat Commun 9:5421|
|Huynh, Mailee; Pak, Chorom; Markovina, Stephanie et al. (2018) Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-?B activity and increases drug resistance in multiple myeloma. J Biol Chem 293:2452-2465|
|Wu, Yirong; Fan, Jun; Peissig, Peggy et al. (2018) Quantifying predictive capability of electronic health records for the most harmful breast cancer. Proc SPIE Int Soc Opt Eng 10577:|
|Fu, Anqi; Oberholtzer, Sydney M; Bagheri-Fam, Stefan et al. (2018) Dynamic expression patterns of Irx3 and Irx5 during germline nest breakdown and primordial follicle formation promote follicle survival in mouse ovaries. PLoS Genet 14:e1007488|
|Jiang, Dawei; Ge, Zhilei; Im, Hyung-Jun et al. (2018) DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury. Nat Biomed Eng 2:865-877|
|Seok, Seung-Hyeon; Ma, Zhi-Xiong; Feltenberger, John B et al. (2018) Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR). J Biol Chem 293:1994-2005|
|Farrell, Emily; Armstrong, Annie E; Grimes, Adrian C et al. (2018) Transcriptome Analysis of Cardiac Hypertrophic Growth in MYBPC3-Null Mice Suggests Early Responders in Hypertrophic Remodeling. Front Physiol 9:1442|
|Net, Jose M; Whitman, Gary J; Morris, Elizabteh et al. (2018) Relationships Between Human-Extracted MRI Tumor Phenotypes of Breast Cancer and Clinical Prognostic Indicators Including Receptor Status and Molecular Subtype. Curr Probl Diagn Radiol :|
|Chang, Julie E; Carmichael, Lakeesha L; Kim, KyungMann et al. (2018) VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clin Lymphoma Myeloma Leuk 18:e61-e67|
|Guerrero, Natalie; Small, Alissa L; Schwei, Rebecca J et al. (2018) Informing physician strategies to overcome language barriers in encounters with pediatric patients. Patient Educ Couns 101:653-658|
Showing the most recent 10 out of 1528 publications